Skip to main content
Top
Published in: Clinical Rheumatology 6/2017

01-06-2017 | Brief Report

Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome

Authors: José Pardos-Gea, Josefina Cortés-Hernández, Jesus Castro-Marrero, Eva Balada, José Ordi-Ros

Published in: Clinical Rheumatology | Issue 6/2017

Login to get access

Abstract

Introduction/objectives autoantibodies to types I and IV collagen have been described in rheumatic fever and infective endocarditis. We tried to elucidate if an autoimmune response against collagens I and IV exists, associated with heart valve disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). A cohort of 172 patients with SLE (n = 79), primary APS (PAPS, n = 83), and secondary APS (n = 10) were assessed for valvulopathy by transthoracic echocardiograms. Autoantibodies to types I and IV collagen were assessed in patients and 50 controls, setting autoantibody positivity at two standard deviations above the mean antibody level of controls. Positive anticollagen IV antibody rate was significantly higher in SLE patients (17.7%) in respect to the rest of groups (PAPS 2.4%, controls 2%; P = 0.001). Percentage of positive autoantibodies to collagen I was similar in SLE and APS cohort of patients with and without valvular disease (48.4 vs 51.6%, respectively; P = 0.45). Percentage of positive autoantibodies to collagen IV was increased but not significantly in SLE and APS cohort of patients with respect to those without valvular disease (62.5 vs 37.5%, respectively; P = 0.08). Mean (standard deviation) levels of positive anticollagen I and IV antibodies did not differ between patients with and without valvular disease (85.6 ± 55 vs 81 ± 85 U/ml, respectively; P = 0.86 for anticollagen I) (0.05 ± 0.02 vs 0.12 ± 0.16 U/ml, respectively; P = 0.34 for anticollagen IV). Our data indicate a lack of association of autoantibodies to types I and IV collagen with heart valve disease in SLE and APS.
Literature
1.
go back to reference Libman E, Sacks B (1924) A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33:701–737CrossRef Libman E, Sacks B (1924) A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33:701–737CrossRef
2.
go back to reference Cervera R, Tektonidou MG, Espinosa G et al. (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. Feb;20(2):165–73. Cervera R, Tektonidou MG, Espinosa G et al. (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. Feb;20(2):165–73.
3.
go back to reference Shapiro RF, Gamble CN, Wiesner KB, Castles JJ, Wolf AW, Hurley EJ, Salel AF et al (1977) Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis 36(6):508–516CrossRefPubMedPubMedCentral Shapiro RF, Gamble CN, Wiesner KB, Castles JJ, Wolf AW, Hurley EJ, Salel AF et al (1977) Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis 36(6):508–516CrossRefPubMedPubMedCentral
4.
go back to reference Bidani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69(6):849–858CrossRefPubMed Bidani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69(6):849–858CrossRefPubMed
5.
go back to reference Ziporen L, Goldberg I, Arad M et al (1996) Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5:196–205CrossRefPubMed Ziporen L, Goldberg I, Arad M et al (1996) Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5:196–205CrossRefPubMed
6.
go back to reference Afek A, Schoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3ß1 integrin in cardiac valvulopathy in primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507CrossRefPubMed Afek A, Schoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3ß1 integrin in cardiac valvulopathy in primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507CrossRefPubMed
7.
go back to reference Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13(7):1637–1652CrossRefPubMed Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13(7):1637–1652CrossRefPubMed
8.
go back to reference Martins TB, Hoffman JL, Augustine NH et al (2008) Comprehensive analysis of antibodies responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 20(39):445–452CrossRefPubMed Martins TB, Hoffman JL, Augustine NH et al (2008) Comprehensive analysis of antibodies responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 20(39):445–452CrossRefPubMed
9.
go back to reference De Buyzere ML, De Scheerder IK, Delanghe JR, Robbrecht JH, Clement DL, Wieme RJ (1989) Measurement of autoimmune response against collagen types I, III, and IV by ELISA, and its application in infective endocarditis. Clin Chem 35(2):246–250PubMed De Buyzere ML, De Scheerder IK, Delanghe JR, Robbrecht JH, Clement DL, Wieme RJ (1989) Measurement of autoimmune response against collagen types I, III, and IV by ELISA, and its application in infective endocarditis. Clin Chem 35(2):246–250PubMed
10.
go back to reference Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed
11.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
12.
go back to reference Pardos-Gea J, Ordi-Ros J, Avegliano G et al (2010) Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus 19:575–582CrossRefPubMed Pardos-Gea J, Ordi-Ros J, Avegliano G et al (2010) Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus 19:575–582CrossRefPubMed
13.
go back to reference Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR (1988) Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue disease, and chronic inflammatory syndromes. Annals of the Rheumatic Disease 47:313–322CrossRef Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR (1988) Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue disease, and chronic inflammatory syndromes. Annals of the Rheumatic Disease 47:313–322CrossRef
14.
go back to reference Stuart JM, Huffstutter EH, Townes AS, Kang AH (1983) Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic disease as measured by I 125-radioimmunoassay. Arthritis Rheum 26:832–840CrossRefPubMed Stuart JM, Huffstutter EH, Townes AS, Kang AH (1983) Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic disease as measured by I 125-radioimmunoassay. Arthritis Rheum 26:832–840CrossRefPubMed
15.
go back to reference Cook AD, Rowley MJ, Wines BD, Mackay IR (1994) Antibodies to the collagen-like region of C1q and type II collagen are independent non-cross-reactive populations in systemic lupus erythematosus and rheumatoid arthritis. J Autoimmun 7(3):369–378CrossRefPubMed Cook AD, Rowley MJ, Wines BD, Mackay IR (1994) Antibodies to the collagen-like region of C1q and type II collagen are independent non-cross-reactive populations in systemic lupus erythematosus and rheumatoid arthritis. J Autoimmun 7(3):369–378CrossRefPubMed
16.
go back to reference Cook AD, Mackay IR, Cicuttini FM, Rowley MJ (1997) IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 24(11):2090–2096PubMed Cook AD, Mackay IR, Cicuttini FM, Rowley MJ (1997) IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 24(11):2090–2096PubMed
17.
go back to reference Manivel VA, Sohrabian A, Wick MC, Mullazehi M, Håkansson LD, Rönnelid J (2015) Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies. Arthritis Res Ther 17:8CrossRefPubMedPubMedCentral Manivel VA, Sohrabian A, Wick MC, Mullazehi M, Håkansson LD, Rönnelid J (2015) Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies. Arthritis Res Ther 17:8CrossRefPubMedPubMedCentral
18.
go back to reference Cui Z, Zhao MH, Jia XY, Wang M, Hu SY, Wang SX, Yu F, Brown KL, Hudson BG, Pedchenko V (2016) Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture’s disease. J Autoimmun 70:1–11CrossRefPubMed Cui Z, Zhao MH, Jia XY, Wang M, Hu SY, Wang SX, Yu F, Brown KL, Hudson BG, Pedchenko V (2016) Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture’s disease. J Autoimmun 70:1–11CrossRefPubMed
19.
go back to reference Petty RE, Hunt DW, Rosenberg AM (1986) Antibodies to type IV collagen in rheumatic diseases. J Rheumatol 13(2):246–253PubMed Petty RE, Hunt DW, Rosenberg AM (1986) Antibodies to type IV collagen in rheumatic diseases. J Rheumatol 13(2):246–253PubMed
20.
go back to reference Mackel AM, de Lustro F, Harper FE, Le Roy EC (1982) Antibodies to collagen in scleroderma. Arthritis Rheum 25:522–531CrossRefPubMed Mackel AM, de Lustro F, Harper FE, Le Roy EC (1982) Antibodies to collagen in scleroderma. Arthritis Rheum 25:522–531CrossRefPubMed
21.
go back to reference Moreland LW, Gay RE, Gay S (1991) Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopathol 60(3):412–418CrossRefPubMed Moreland LW, Gay RE, Gay S (1991) Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopathol 60(3):412–418CrossRefPubMed
22.
go back to reference Fukasawa Y, Kano S (1993) Anti-type II collagen antibodies in collagen disease. Rinsho Byori 41(8):876–881PubMed Fukasawa Y, Kano S (1993) Anti-type II collagen antibodies in collagen disease. Rinsho Byori 41(8):876–881PubMed
23.
go back to reference Sjoholm AG, Martensson U, Sturfelt G (1997) Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 24(5):871–878PubMed Sjoholm AG, Martensson U, Sturfelt G (1997) Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 24(5):871–878PubMed
24.
go back to reference Blank M, Krause I, Magrini L et al (2006) Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology 45:833–841CrossRefPubMed Blank M, Krause I, Magrini L et al (2006) Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology 45:833–841CrossRefPubMed
Metadata
Title
Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome
Authors
José Pardos-Gea
Josefina Cortés-Hernández
Jesus Castro-Marrero
Eva Balada
José Ordi-Ros
Publication date
01-06-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3594-9

Other articles of this Issue 6/2017

Clinical Rheumatology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.